Experiences with
Oral chemotherapy17,339 public posts
Want to take advantage of all our features? Just log in!
or
FDA approval Alecensa (alectinib) following surgery for people with early stage ALK positive NSCLC
On April 18, 2024, the U.S. Food and Drug Administration (FDA) approved Alecensa (alectinib) following surgical resection for people living with early-stage ALK-positive non-small cell lung cancer (NSCLC).
The approval is based on results from the ALINA study (NCT03456076). Participants with stage